Trials / Unknown
UnknownNCT04975204
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
A Phase I Clinical Trial Evaluating the Tolerance and Pharmacokinetics of TQB3909 Tablets in Patients With Relapsed or Refractory Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 126 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3909 Tablets | TQB3909 is an inhibitor targeting BCL-2 protein |
Timeline
- Start date
- 2022-02-18
- Primary completion
- 2022-12-01
- Completion
- 2024-08-01
- First posted
- 2021-07-23
- Last updated
- 2022-03-07
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04975204. Inclusion in this directory is not an endorsement.